

Proveca Pharma Ltd. 2 Dublin Landings North Wall Quay Dublin 1 D01 V4A3 Ireland

Company Number IE634819

Tel: +353 1 513 6233 Email: info@proveca.com

# Proveca Pharma Ltd. Transfer of Value Disclosure 2023

### Methodological Note – Austria

### **Introduction**

Proveca Pharma Limited disclose Transfers of Value ('ToVs') made to Healthcare Professionals ('HCPs') and Healthcare Organisations ('HCOs') in line with the requirements of the European Federation of Pharmaceutical Industries Associations ('EFPIA') code and the Pharmig code of conduct.

ToVs means direct/indirect service or any direct/indirect in cash or in-kind performances, or any direct/indirect performances of any other nature that are provided directly or indirectly to any recipient (for instance, HCP/HCO).

### **Definitions**

Recipients	Healthcare Professional ('HCP')
	Any natural person(s) authorized to administer, to
	dispense, and to prescribe medicinal products such as
	doctors, pharmacists, dental practitioners, veterinarians,
	dentists, midwives, nursing professionals, medical
	technicians, medical service professionals, and other
	medical services organizations, provided that such
	medicinal products are necessary for the discharge of
	their duties.
	Healthcare Organisation ('HCO')
	Any legal person, association, or organization
	predominantly comprised of healthcare professionals
	such as hospitals, clinics, foundations, universities, or
	teaching institutions which render medical services or
	perform medical research, irrespective of their legal or
	organizational form, with the exception of patient
	organizations.
	Patient Organisation ('PO')
	Voluntary, non-profit entities mainly composed of
	patients and/or caregivers and/or other patient
	organizations whose sole purpose is to represent the
	interests of patients and/or caregivers and which exist or
	were founded to serve those interests.
Kinds of ToVs	Contribution to Costs related to Events
	Support providing or covering the costs of meals, travel,
	accommodation and/or registration fees to support the

attendance of an individual HCP or PO representative to an Event organised or created by Proveca and/or a Third Party.

### **Donations and Grants**

Funds, assets, or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient to provide goods or services to the benefit of the donor in return.

#### **Sponsorship**

Support provided by or on behalf of Proveca, when permitted by law, as a contribution to support an activity (including an Event) performed, organised or created by a HCO, a PO, or a Third Party.

#### **Fees for Service and Consultancy**

ToVs resulting from or related to contracts between Proveca and HCPs/HCOs/POs under which such HCPs/HCOs/POs provide any type of services to Proveca or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand ToVs relating to expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.

#### Scope

Products concerned	Prescription-Only Medicines (POMs).
Companies concerned	Proveca Pharma Ltd
(Collectively 'Proveca')	2 Dublin Landings
	North Wall Quay
	Dublin 1
	D01 V4A3
	Ireland
	Proveca Ltd
	WeWork
	One St Peter's Square
	Manchester
	M2 3DE
	UK
Excluded ToVs	Without limitation, ToVs that:
	I. are solely related to over-the-counter medicines;
	II. are not listed in Section 23.05 of the EFPIA Code,
	such as Items of Medical Utility (governed by
	Article 17), meals (governed by Article 10,
	especially Section 10.05), Medical Samples
	(governed by Article 19); or
	III. are part of ordinary course purchases and sales
	of Medicinal Products by and between a Member
	Company and a HCP (such as a pharmacist) or a
	HCO do not fall within the scope of the disclosure
	obligation.

ToVs date	Reporting period for ToVs is the calendar year 2023.
Direct ToVs	ToVs made directly by Proveca for the benefit of a
	Recipient.
Indirect ToVs	ToVs made on behalf of Proveca for the benefit of a
	Recipient, or those made through a Third Party and
	where Proveca knows or can identify the Recipient that
	will benefit from the ToV.
Non-monetary ToVs	No non-monetray ToVs were made during the reporting
	period.
Cross-border activities	Disclosures must be made pursuant to the National Code
	of the country where the Recipient has its professional
	address.
Research and development	ToVs to HCPs or HCOs related to the planning or conduct
	of:
	I. non-clinical studies (as defined in OECD Principles
	on Good Laboratory Practice);
	II. clinical trials (as defined in Regulation 536/2014);
	or
	III. non-interventional studies that are prospective in
	nature and that involve the collection of patient
	data from or on behalf of individual, or groups of,
	HCPs specifically for the study.

## Legal basis

Consent	

# Form of disclosure

Date of publication	30 <sup>th</sup> June 2024
Disclosure platform	Proveca company website
Disclosure language	English

# Financial data

Currency	ToVs are disclosed in Euro (€). Where the original
	payment was made in another currency, the sum is
	converted to Euro at the exchange rate prevailing at the
	time of the original payment.
VAT	ToVs are disclosed exclusive of VAT.

[June 2024]